

DAFTAR PUSTAKA

- Aini, N., Setiawan, B., Sandra, F., 2008, *Karakteristik Biologis dan Diferensiasi Stem cell: Fokus pada Mesenchymal stem cell*, cdk,161
- Brand S, Beigel F, Olszak T, et al, 2006, “IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration”, *Am J Physiol Gastrointest Liver Physiol*, 290:G827–G838.
- Caulfield, T., Ogbogu, U., Nelson, E., 2007, *Stem cell Research Ethics: Consensus Statement on Emerging Issues*, *J Obstet Gynaecol Can*, 843–848
- Cuschieri J., Maier RV., 2005, “Mitogen-activated protein kinase (MAPK)”, *Crit Care Med.*; 33:S417–S419.
- Dantuma, E., Merchant, S., Sugaya, K., 2010, *Stem cells for The Treatment of Neurodegenerative Diseases*, doi:10.1186/scrt37, dalam <http://www.stemcellres.com/content/1/5/37>, diakses pada tanggal 2 Juli 2015.
- Diez, J.M., Bauman, E., Gajardo, R., 2015, *Culture of Human Mesenchymal stem cells using a candidate pharmaceutical grade xeno-free cell culture supplement derived from industrial human plasma pools*, *stem cell research and therapy*, doi: 10.1186/s13287-015-0016-2.
- Dominici, M., Le Blanc, K., Mueller I., *et.al.*, 2006, *Minimal Criteria for Defining Multipotent Stromal Cells. The International Society for Cellular Therapy position statement.*, NCBI, 16923606.
- Ennis W.J., Sui A., Bartholomew A., 2013, “*Stem Cells and Healing: Impact on Inflammation*”, *Adv Wound Care (New Rochelle)*; 2(7): 369–378.
- Goligorsky M.J., 2011, *Regenerative Nephrology*, Elsevier, UK, 226.
- Halim, D., Murti, H., Sandra, F., 2010, *Stem cell Dasar Teori & Aplikasi Klinis*, Erlangga Medical Series, Jakarta
- Hallenbeck JM., 2002, “The many faces of tumor necrosis factor in stroke”, *Nat Med*; 8:1363–1368.
- Han B., Fu XB., Han B., Lei YH., Chen W., Sun TZ., 2007, “*Chemotactic effects of burn rat serum on mesenchymal stem cells derived from different sources*”, *Zhonghua Shao Shang Za Zhi*; 23(1):25-8.

- Huang H., Zhao N., Xu X., Xu Y., Li S., Zhang J., Yang P., 2011, "Dose-specific effects of tumor necrosis factor alpha on osteogenic differentiation of *mesenchymal stem cells*", *Cell Prolif*; 44(5):420-7.
- Jiang Y, Jahagirder BN, Reindhardt RL, *et al.* 2002. *Pluripotency of mesenchymal stem cells derived from adult bone marrow.*
- Lee M.J., Kim J., Kim M.Y., Bae Y.S., Ryu S.H., Lee T.G., Kim J.H., 2010, "Proteomic analysis of tumor necrosis factor-alpha-induced secretome of human adipose tissue-derived mesenchymal stem cells", *J. Proteome Res.*; 9: 1754–1762.
- Locksley R.M., Killeen N., Lenardo M.J., 2001, "The TNF and TNF receptor superfamilies: integrating mammalian biology," *Cell*; 104: 487–501.
- Marr, R.A., Thomas, R.M., Peterson, D.A., 2010, *Insights into Neurogenesis and Aging: Potential*
- Morrison SJ, Kimble J. 2006. *Asymmetric and symmetric stem-cell divisions in development and cancer.* Nature.
- Mummery, C., Wilmot, I., Stolpe, A., 2011, *Stem cells Scientific Facts and Fiction*, Elsevier Inc., London, 88-107
- Putra, A, 2012, *Molekuler Onkogenesis: Konsep genetik, Virus, Radiasi-Kimia, Mutasi Gen, Epigenetik dan Signalling*, Terbitan Pertama, Unissula Press, Semarang, 89-103.
- Scott, M.A., Nguyen, V.T., Levi, B., 2011, *Current Methods of Adipogenic Differentiation of Mesenchymal stem cells*, *Stem cells Dev*, doi: 10.1089/scd.2011.0040
- Setiawan, B., 2006, *Aplikasi Terapeutik Sel Stem Embrionik pada Berbagai Penyakit Degeneratif*, cdk, 153
- Shenghui H, Nakada D, and Morrison SJ. 2009. *Mechanisms of Stem cell Self-Renewal Annu. Rev. Cell Dev. Biol*
- WHO (World Health Organization), 2014, *Global Status Report On Noncommunicable diseases 2014.*
- XuriTM MSC Medium, 2013, "A defined, serum-free (SF), xeno-free (XF) medium, designed to support the expansion of human mesenchymal stem cells (hMSC)", GE Healthcare Companies, Tokyo Japan.

Yamashita YM, Yuan H, Cheng J, and Hunt AJ., 2010, Polarity in stemcell division. *Asymmetric Stem cell Division in Tissue Homeostasis*. 1-15

Zhang D, Fan G, Zhou X, Zhao T, Pasha Z, Xu M, *et al.* 2008. *Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium*. *J Mol Cell Cardiol*.